A call for national and regional containment, recovery and prevention
A compendium of TB REACH case studies, lessons learned and a monitoring and evaluation framework.
Accessed November 2017.
The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
A Decade of Tracking Progress for Maternal, Newborn and Child Survival The 2015 Report
UNAIDS 2018, Guidance
Indicators for monitoring the
2016 Political Declaration on Ending AIDS
This document defines the framework for Malawi’s National HIV Programs. Considering public health benefits and risks, as well as funding and resource implications, deviations from these guidelines are not supported by the Ministry of Health.
Reporting period: January 2008-December 2010
Accessed: 29.09.2019
Tuberculosis cases, TB deaths
To deliver on the Global Fund Strategy milestones
for 2028 and ensure we keep the SDG 3 target
within reach, we need to raise US$18 billion to
fund the Global Fund’s next three-year grant cycle.
Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV prevention overall, as it allows people to choose a method that they prefer.
In this guideline, WHO recommends an offering long-acting injectable lenacapavir (LEN...) as an additional HIV prevention choice, as part of combination HIV prevention approaches. LEN, administered twice a year as PrEP, has been shown to be highly effective at reducing the risk of HIV acquisition. In this guideline, WHO also recommends using HIV rapid diagnostic tests (RDTs) for individuals initiating or continuing long-acting injectable PrEP, such as LEN and long acting injectable cabotegravir (CAB-LA). Flexible HIV testing approaches are essential for ensuring that testing does not become a barrier to accessing or continuing PrEP, including long-acting injectable options.
more
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex B